Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

“One pill, once daily”: what clinicians need to know about Atripla™

Authors Clay PG, Taylor TAH, Glaros AG, McRae M, Williams C, McCandless D, Oelklaus M

Published 11 April 2008 Volume 2008:4(2) Pages 291—302

DOI https://doi.org/10.2147/TCRM.S1708

Patrick G Clay1,2, Tracey AH Taylor1, Alan G Glaros3, MaryPeace McRae1, Charlott Williams2, Don McCandless1, Maurice Oelklaus4

1Department of Pharmacology/Microbiology; 2Department of Clinical Research; 3Division of Basic Sciences; 4College of Medicine, Kansas City University of Medicine and Biosciences, Kansas City, MO, USA

Abstract: As the number of persons chronically prescribed antiretrovirals has grown and the realization that antiretrovirals are required to be continued for life, pharmaceutical manufacturers have developed new classes of agents, improved the pharmacokinetics of marketed products through dosing reformulations, and in an effort to maximize success with respect to adherence, compiled into a single dosing unit all necessary elements for an antiretroviral regimen. Atripla™ represents the first ever fixed-dose combination antiretroviral available. This article reviews currently available data on this agent, the impact of resistance on clinical use and implementation, as well as extensive descriptions of the pharmacokinetics, adverse effects and drug-interactions warranting consideration. Whether beginning in a naïve patient or switching from other regimens for tolerability issues, Atripla™ represents a viable option. Its demonstrated advantages with respect to lipid and hematologic parameters and equivalent incidence of renal toxicity are tempered by the findings of bone mineral density decreases, however. Combining multiple mechanisms of action in a single dosing unit appears to improve efficacy, increase the likelihood for adherence and maintain viral suppression compared to administering these agents independently. It is suggested other pharmaceutical companies assess the potential to replicate this for the remaining antiretrovirals.

Keywords: Atripla™, antiretrovirals, HIV

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Relationship between grades of macular perfusion and foveal thickness in branch retinal vein occlusion

Sakimoto S, Kamei M, Suzuki M, Yano S, Matsumura N, Sakaguchi H, Gomi F, Nishida K

Clinical Ophthalmology 2013, 7:39-45

Published Date: 31 December 2012

Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets

Kounnis V, Ioachim E, Svoboda M, Tzakos A, Sainis I, Thalhammer T, Steiner G, Briasoulis E

OncoTargets and Therapy 2011, 4:27-32

Published Date: 8 April 2011

Pharmacological management of acute bronchiolitis

Melvin Wright, Charles J Mullett, Giovanni Piedimonte

Therapeutics and Clinical Risk Management 2008, 4:895-903

Published Date: 10 October 2008

Corrigendum

Dove Medical Press Editorial

Clinical Interventions in Aging 2008, 3:397-397

Published Date: 6 June 2008

Severe supraaortal atherosclerotic disease resembling Takayasu’s Arteritis

Bernhard Kis, Thomas Liebig, Peter Berlit

Vascular Health and Risk Management 2007, 3:351-354

Published Date: 15 July 2007

Prophylaxis of migraine

Ivan Garza, Jerry W Swanson

Neuropsychiatric Disease and Treatment 2006, 2:281-291

Published Date: 15 September 2006